Tela Bio Inc
$ 0.62
-1.74%
21 Apr - close price
- Market Cap 28,231,200 USD
- Current Price $ 0.62
- High / Low $ 0.64 / 0.59
- Stock P/E N/A
- Book Value 0.14
- EPS -0.83
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -2.23 %
- 52 Week High 2.20
- 52 Week Low 0.50
About
TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$2.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-19 | 2025-11-13 | 2025-08-11 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-09 | 2023-05-11 |
| Reported EPS | -0.17 | -0.19 | -0.22 | -0.25 | -0.23 | -0.42 | -0.51 | -0.23 | -0.53 | -0.45 | -0.46 | -0.63 |
| Estimated EPS | -0.175 | -0.16 | -0.18 | -0.2075 | -0.222 | -0.4 | -0.47 | -0.5 | -0.43 | -0.49 | -0.53 | -0.56 |
| Surprise | 0.005 | -0.03 | -0.04 | -0.0425 | -0.008 | -0.02 | -0.04 | 0.27 | -0.1 | 0.04 | 0.07 | -0.07 |
| Surprise Percentage | 2.8571% | -18.75% | -22.2222% | -20.4819% | -3.6036% | -5% | -8.5106% | 54% | -23.2558% | 8.1633% | 13.2075% | -12.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TELA
2026-04-21 19:40:03
TELA Bio (NASDAQ: TELA) announced it will report its first-quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors need to register online in advance to participate in the call.
2026-04-21 19:40:03
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its first quarter 2026 financial results on Tuesday, May 12, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Investors can register online to listen to the call.
2026-04-17 17:10:10
TELA Bio has introduced OviTex Long-Term Resorbable, a new reinforcement solution featuring PLGA reinforcement, designed to enhance robotic surgery platforms. This product aims to improve natural integration and long-term performance in surgical applications, thereby benefiting patients and surgeons utilizing advanced robotic technologies. This launch follows earlier initiatives by TELA Bio to introduce new hernia treatments and advocate for case-specific hernia repair strategies.
2026-04-14 15:40:15
TELA Bio is advocating for case-specific approaches to hernia repair, urging medical professionals to discuss optimal solutions at the upcoming Intuitive Connect event. The company emphasizes that different hernia types, from inguinal to complex CAWR, necessitate varied products and surgical strategies. TELA Bio aims to utilize this platform to advance nuanced surgical decision-making and innovation in hernia treatments.
2026-04-01 20:09:53
TELA Bio has introduced a new hernia treatment solution designed to offer consistent performance and a simplified approach. The company emphasized its focus on reducing complexity in hernia care, acknowledging the need for careful consideration in medical solutions. Further details about the product's clinical impact are expected to be released soon.
2026-03-29 21:09:15
Piper Sandler has reduced its price target for TELA Bio (NASDAQ:TELA) from $1.25 to $1.00, maintaining a Neutral rating, due to the company's lowered 2026 revenue outlook after missing Q4 2025 revenue estimates. The firm acknowledges TELA Bio's strong product and increased sales team headcount but awaits signs of accelerating business momentum before a sentiment change. Separately, Jefferies also lowered its price target for TELA Bio to $3.25 from $4.00, citing a slower growth outlook, despite the company surpassing EPS estimates in Q4 2025.
